Kiniksa Pharmaceuticals Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Kiniksa Pharmaceuticals's estimated annual revenue is currently $19.8M per year.(i)
  • Kiniksa Pharmaceuticals's estimated revenue per employee is $81,818
  • Kiniksa Pharmaceuticals's total funding is $400M.
  • Kiniksa Pharmaceuticals's current valuation is $780.5M. (January 2022}

Employee Data

  • Kiniksa Pharmaceuticals has 242 Employees.(i)
  • Kiniksa Pharmaceuticals grew their employee count by 7% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Kiniksa is a publicly traded biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. We have a pipeline of product candidates across various stages of development focused on autoinflammatory and autoimmune conditions that have the potential to address multiple indications. We are relentless and focused on putting patients at the center of everything we do and strive to develop life-changing medicines. We are focused on hiring and retaining a highly skilled team that has extensive experience and specific skill sets relating to the selection, development, and commercialization of transformative therapies. Whether in development, research, manufacturing, technical operations, or general / administrative functions, we depend on a brilliant team to support our mission of building a global, generational company. Our benefits are competitive, and we offer dynamic career opportunities across our organization fostering a culture that embraces passion and rapid execution.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Kiniksa Pharmaceuticals News

12-Sep-19 - Here's Why Kiniksa Pharmaceuticals, Ltd. (KNSA) Dropped -2.9%

For its latest trading sesion, Kiniksa Pharmaceuticals, Ltd. (KNSA) dropped by -2.9% – here is what that looked like (as of 2019-09-16): ...

12-Sep-19 - Earnings According to Quant For TransMedics Group, Inc. (NasdaqGM:TMDX), Kiniksa Pharmaceuticals, Ltd. (NasdaqGS:KNSA)

In terms of EBITDA Yield, Kiniksa Pharmaceuticals, Ltd. (NasdaqGS:KNSA) currently has a value of -0.644628. This value is derived by dividing ...

12-Sep-19 - A Look at Kiniksa Pharmaceuticals, Ltd. (NasdaqGS:KNSA)'s -0.649188 Earnings Yield & Data Deep Dive

The Earnings Yield for Kiniksa Pharmaceuticals, Ltd. (NasdaqGS:KNSA) stands at -0.649188. Earnings Yield helps investors measure the ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding